Austin, TXNCT06479863Now EnrollingIRB Ready

Sporadic Inclusion Body Myositis (sIBM) Clinical Trial in Austin, TX

Access cutting-edge sporadic inclusion body myositis (sibm) treatment through this early phase 1 clinical trial at a research site in Austin. Study-provided care at no cost to qualified participants.

Sponsored by Austin Neuromuscular Center

Quick Self-Assessment

See if you qualify for this Austin location

Preparing your pre-screening questions…

Expert Care in Austin

Access sporadic inclusion body myositis (sibm) specialists at no cost

IRB Approved

This study follows strict safety protocols and ethical guidelines

No-Cost Care

All study-related sporadic inclusion body myositis (sibm) treatment provided free

Apply for This Austin Location

Check if you qualify for this sporadic inclusion body myositis (sibm) clinical trial in Austin, TX

Secure & Confidential

Your information is protected and will only be shared with the research team.

Why Participate?

  • No-Cost Study Care

  • Local to Austin

    Convenient for TX residents

  • Cutting-Edge Treatment

    Access to innovative therapies

  • Expert Medical Care

    Close monitoring by specialists

  • Possible Compensation*

    For time and travel

*Compensation varies by study. Confirm details with coordinator.

Simple Process

  1. 1Submit this form
  2. 2Phone screening
  3. 3Visit Austin site if eligible
  4. 4Begin participation

About This Sporadic Inclusion Body Myositis (sIBM) Study in Austin

To evaluate the efficacy of Pozelimab/Cemdisiran combination therapy in patients with sIBM

Sponsor: Austin Neuromuscular Center

Who Can Participate

Inclusion Criteria

1\. Age ≥45 years to 75 years of age 2. Diagnosed with sIBM based on the ENMC IBM Research Diagnostic Criteria 3. Willing and able to comply with clinic visits and study-related procedures. 4. Provide informed consent signed by the study patient or legally acceptable representative. 5\. Able to understand and complete study-related questionnaires. 6. Able to ambulate at least 20 ft/6 meters with or without assistive device Once arising from the chair, the participant may use any walking device, i.e. walker/frame, cane, crutches, or braces. They cannot be supported by another person and cannot use furniture or walls for support. 7\. If female, the subject must be: (a) surgically sterilized via hysterectomy, bilateral oophorectomy, or bilateral tubal ligation. or (b) of childbearing potential and using a birth control method, such as: •Combined (estrogen and progestogen-containing) hormonal. contraception associated with inhibition of ovulation: o Oral
Intravaginal
Transdermal
Progestogen-only hormonal contraception associated with inhibition of ovulation:
Implantable • Intrauterine device • Intrauterine hormone-releasing system • Bilateral tubal occlusion
Vasectomized partner
Sexual abstinence or of non-childbearing potential (i.e., no menses for ≥12 consecutive months without any other underlying medical cause) The subject must agree to continue using her selected method of birth control with her sexual partner during the study and for 120 days after study completion. 8\. If male, the subject must have had a vasectomy or must use a reliable method of birth control with their partner or maintain total abstinence from sexual intercourse. The subject must agree to continue using his selected method of birth control with his sexual partner during the study and for 120 days after the study completion.

Exclusion Criteria

1\. Other neurological conditions (e.g., hemiplegia post-stroke, Parkinson's Disease) or musculoskeletal conditions (e.g., severe osteoarthritis) causing mobility impairment. 2\. Any known active malignancy 3. Significant illness or history of significant illness that, in the investigator's opinion, may adversely affect the patient's participation in this study. 4\. Any previous treatment with a complement inhibitor 5. History of meningococcal disease 6. No documented meningococcal and pneumococcal vaccination within 5 years prior to screening visit unless vaccination will be administered during the screening period and prior to initiation of study treatment. 7\. Known contraindication to meningococcal (group ACWY conjugate and group B vaccines) and pneumococcal vaccines. 8\. Subject unwilling to receive meningococcal and pneumococcal vaccinations. 9. Patients with screening serum ALT levels \>3×ULN and/or total bilirubin \>2×ULN (unless bilirubin elevation is due to suspected Gilbert's syndrome). 10\. Active or recent systemic infection within 2 weeks prior to Baseline. 11. Pregnant, planning to become pregnant, or lactating female subjects. 12. Treatment with an experimental drug within 30 days or 5 half-lives of the experimental drug. 13\. Participation in another concurrent interventional clinical trial. 14. Subjects with functional and anatomic asplenia 15. Subjects with positive tests for hepatitis B, hepatitis C, or HIV at screening 16. Presence of active or latent tuberculosis 17. Presence of any other form of myositis or myopathy or myositis overlap with other autoimmune diseases 18. Presence of other autoimmune or autoinflammatory diseases

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in Austin?

Yes, this clinical trial (NCT06479863) has an active research site in Austin, TX that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

Sporadic Inclusion Body Myositis (sIBM) Treatment Options in Austin, TX

If you're searching for sporadic inclusion body myositis (sibm) treatment options in Austin, TX, this clinical trial (NCT06479863) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our Austin research site is actively enrolling participants for this early phase 1 clinical trial. You'll receive care from experienced sporadic inclusion body myositis (sibm) specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all sporadic inclusion body myositis (sibm) clinical trials near you to find additional studies recruiting in your area.

More Alzheimers Disease Trials in Austin, TX

See all alzheimers disease clinical trials recruiting in Austin — not just this study.

Browse Alzheimers Disease Trials in Austin →

Browse More Trials by Condition

Alzheimers Disease TrialsRheumatoid Arthritis TrialsMyositis TrialsAtopic Dermatitis TrialsInterstitial Cystitis TrialsBatten Disease TrialsAll Conditions →

Ready to Join in Austin?

Take the first step toward participating in this groundbreaking clinical trial

Secure · Expert Care · Austin, TX